Drug Trial Radar · NCT05994690
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
905
Planned (sponsor's estimate)
Start
Jul 14, 2023
Primary completion
Mar 2031
Study completion Dec 2035
Sponsor
- Lead sponsor
- Princess Maxima Center for Pediatric OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
Conditions
- Acute Myeloid Leukemia in Children
Interventions
Standard Intervention RcDrug
3 consolidation courses (HAM + HA3E + FLA)
Investigational Intervention RcDrug
2 consolidation courses (HAM + FLA)
Standard Intervention RiDrug
No addition of GO to first induction course
Investigational Intervention RiDrug
Addition of GO to first induction course
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overarching primary objectiveTime frame: 5 years
- Primary objective Randomisation ConsolidationTime frame: 5 years
- Primary objective Randomisation InductionTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Princess Máxima Center for pediatric oncology
Utrecht, Utrecht, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.